Sign in Subscribe
Pharmaceutical industry

Gastrotech Pharma and Eli Lilly Collaborate to Develop Novel IBS and Functional Dyspepsia Treatments

Strategic Insights

— 1 min read

Gastrotech Pharma and Eli Lilly have entered a collaboration agreement to continue the development of proprietary peptides targeting irritable bowel syndrome (IBS) and functional dyspepsia. The partnership will focus on the ongoing clinical phase II trial of a glucagon-like peptide-1 (GLP-1) analogue in IBS patients with moderate-to-severe pain in five medical centers in Sweden and Denmark. Lilly will manufacture the clinical compound and has an option to further develop and commercialize products under the agreement. Gastrotech Pharma has the potential to receive milestone payments and royalties on sales.

Key Takeaways:

  • Gastrotech Pharma and Eli Lilly have formed a collaboration to develop proprietary peptides for IBS and functional dyspepsia.
  • The partnership will continue the clinical phase II trial of a GLP-1 analogue in IBS patients with moderate-to-severe pain.
  • Lilly will manufacture the clinical compound and has the option to further develop and commercialize products under the agreement.
  • Gastrotech Pharma may receive milestone payments and royalties on sales.
  • The trial is being conducted in five medical centers in Sweden and Denmark.
  • Glucagon-like peptide-1 (GLP-1) acts by reducing gastrointestinal motor activity, which is believed to alleviate pain in IBS patients.
  • The collaboration agreement was announced on April 26, 2004.
  • Dr. Claes Post, CEO of Gastrotech Pharma, highlighted Lilly's experience in the GLP-1 field and its ability to develop and commercialize products.

Statistics:

  • The clinical trial is being conducted in five medical centers in Sweden and Denmark.
  • The trial is a double-blind, placebo-controlled, clinical phase II trial.
  • 50% of IBS patients experience moderate-to-severe pain, which is a target benefit of the GLP-1 analogue.
  • Functional dyspepsia affects approximately 10% of the global population.
  • The GLP-1 analogue has shown promise in reducing gastrointestinal motor activity and alleviating pain in IBS patients.

Sources:

  • "Gastrotech Pharma, A/S, gets deal with Eli Lilly and Co. (LLY) for irritable bowel syndrome (IBS) and functional dyspepsia." NewsRx.com & NewsRx.net, April 26, 2004.
  • This article was prepared by Health & Medicine Week editors from staff and other reports. Copyright 2004, Health & Medicine Week via NewsRx.com & NewsRx.net.

Read more